BioMarin Pharmaceutical (BMRN) Tops Q3 Earnings Estimates

Core Insights - BioMarin Pharmaceutical reported quarterly earnings of $0.12 per share, exceeding the Zacks Consensus Estimate of a loss of $0.15 per share, but down from $0.91 per share a year ago [1] - The earnings surprise was +180.00%, and the company has surpassed consensus EPS estimates in all four of the last quarters [2] - Revenue for the quarter was $776.13 million, slightly missing the Zacks Consensus Estimate by 1.05%, but up from $745.74 million year-over-year [3] Earnings Performance - The company has consistently exceeded consensus EPS estimates, achieving this in four consecutive quarters [2] - The current consensus EPS estimate for the upcoming quarter is $0.97, with expected revenues of $819.69 million, and for the current fiscal year, the EPS estimate is $3.54 on revenues of $3.18 billion [8] Stock Performance and Outlook - BioMarin shares have declined approximately 17.1% year-to-date, contrasting with the S&P 500's gain of 15.5% [4] - The stock currently holds a Zacks Rank 4 (Sell), indicating expectations of underperformance in the near future [7] Industry Context - The Medical - Biomedical and Genetics industry, to which BioMarin belongs, is currently ranked in the top 38% of over 250 Zacks industries, suggesting a favorable industry outlook [9] - The performance of BioMarin's stock may be influenced by the overall industry outlook and trends in earnings estimate revisions [6][9]